Open access
Oct 2026
A Phase III, Open-Label, Single-Arm, Multicentric Study of Tildrakizumab in Indian Patients with Moderate-to-Severe Plaque Psoriasis.
In this short-term, single-arm bridging study, tildrakizumab 100 mg demonstrated sustained skin clearance and meaningful QoL improvement through week 28 after three doses, with a favourable safety profile in Indian patients.
Sharath Kumar, Surendra Kumar, V. Krishna et al.
· Dermatologic Therapy · 0 citations